For example, osimertinib, a selective covalent inhibitor for the drug-resistant mutant (T790M) of EGFR, has been recently approved by the FDA for treating metastatic NSCLC (Figure 1A) [11]. Here, EGFR is linked to non-small cell lung carcinoma.